Correlation of long interspersed element-1 open reading frame 1 and c-Met proto-oncogene protein expression in ovarian cancer.
Expression
LINE-1 ORF1
Methylation
Ovarian cancer
c-Met
Journal
Genes & genomics
ISSN: 2092-9293
Titre abrégé: Genes Genomics
Pays: Korea (South)
ID NLM: 101481027
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
23
04
2019
accepted:
26
07
2019
pubmed:
8
8
2019
medline:
19
3
2020
entrez:
8
8
2019
Statut:
ppublish
Résumé
Hypomethylation of long interspersed nuclear element-1 (LINE-1) is closely related to certain cancers and concerns with aggressive tumor behavior. Previously, we reported LINE-1 open reading frame-1 (ORF1) protein level was significantly up-regulated in ovarian cancers compared with normal ovary. Hypomethylation of local LINE-1 sequence has been reported to reactivate MET proto-oncogene in colon cancers and hepatocellular carcinoma. However, the relationship between LINE-1 and c-MET expressions in ovarian cancer is not yet studied. Here, we analyzed the expression patterns of LINE-1 ORF1 and c-Met protein in ovarian cancer tissue microarrays containing 208 surgical specimens including normal ovary and malignant ovarian cancers. The expressions of both LINE-1 ORF1 and c-Met protein were significantly increased in ovarian cancers and peaked in early stage of tumor. Other clinical data including age and tumor types were not significantly related with both proteins. Co-relationship between LINE-1 ORF1 and c-Met protein was significant (p = 0.03) but several patients show different expression patterns. These results propose that LINE-1 ORF1 significantly activates c-Met but not in all cases, suggesting other factors may be involved simultaneously.
Sections du résumé
BACKGROUND
Hypomethylation of long interspersed nuclear element-1 (LINE-1) is closely related to certain cancers and concerns with aggressive tumor behavior. Previously, we reported LINE-1 open reading frame-1 (ORF1) protein level was significantly up-regulated in ovarian cancers compared with normal ovary. Hypomethylation of local LINE-1 sequence has been reported to reactivate MET proto-oncogene in colon cancers and hepatocellular carcinoma. However, the relationship between LINE-1 and c-MET expressions in ovarian cancer is not yet studied.
METHOD
Here, we analyzed the expression patterns of LINE-1 ORF1 and c-Met protein in ovarian cancer tissue microarrays containing 208 surgical specimens including normal ovary and malignant ovarian cancers.
RESULTS
The expressions of both LINE-1 ORF1 and c-Met protein were significantly increased in ovarian cancers and peaked in early stage of tumor. Other clinical data including age and tumor types were not significantly related with both proteins. Co-relationship between LINE-1 ORF1 and c-Met protein was significant (p = 0.03) but several patients show different expression patterns.
CONCLUSIONS
These results propose that LINE-1 ORF1 significantly activates c-Met but not in all cases, suggesting other factors may be involved simultaneously.
Identifiants
pubmed: 31388980
doi: 10.1007/s13258-019-00858-y
pii: 10.1007/s13258-019-00858-y
doi:
Substances chimiques
MAS1 protein, human
0
Proto-Oncogene Mas
0
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1293-1299Références
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
pubmed: 21685461
Jpn J Clin Oncol. 2000 Jul;30(7):306-9
pubmed: 11007163
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):976-84
pubmed: 18021219
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):711-7
pubmed: 17944913
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Int J Cancer. 2011 Jan 1;128(1):33-9
pubmed: 20602342
Ann Surg Oncol. 2014 Dec;21 Suppl 4:S729-35
pubmed: 24992910
Ann Surg. 2013 Mar;257(3):449-55
pubmed: 23023202
Neoplasia. 2010 Jan;12(1):1-10
pubmed: 20072648
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2555-64
pubmed: 18842996
Lab Invest. 2011 Jan;91(1):124-37
pubmed: 20661229
PLoS One. 2013;8(3):e57724
pubmed: 23469222
Oncogene. 2005 Nov 3;24(48):7213-23
pubmed: 16170379
Int J Cancer. 1994 Sep 1;58(5):658-62
pubmed: 8077049
Cancer Res. 2007 Feb 15;67(4):1670-9
pubmed: 17308108
Cancer Res. 2004 Jul 1;64(13):4472-80
pubmed: 15231656
Gut. 2014 Apr;63(4):635-46
pubmed: 23704319
J Clin Oncol. 2011 Dec 20;29(36):4837-8
pubmed: 22042966
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Am J Pathol. 2014 May;184(5):1280-6
pubmed: 24607009
PLoS Genet. 2010 Apr 22;6(4):e1000917
pubmed: 20421991
Int J Cancer. 2018 Dec 1;143(11):2838-2848
pubmed: 30144023
Int J Cancer. 2012 Sep 15;131(6):1323-31
pubmed: 22120154
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
Clin Cancer Res. 2010 Nov 1;16(21):5114-23
pubmed: 20978145
Int J Mol Sci. 2013 Apr 15;14(4):8213-27
pubmed: 23591839
Clin Cancer Res. 2011 Jun 15;17(12):4042-51
pubmed: 21551255